Compare AbCellera Biologics Inc (ABCL) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

FNGU is a leveraged exchange-traded note tracking the FANG+ Index, currently trading at $27.39, up 3.4% over the past day. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and short-term RSI suggests caution. Recent news highlights extreme volatility, with a 16% single-session drop reported on June 5, 2026, underscoring the risks of its 3x leverage structure.

The outlook for FNGU is highly speculative, offering amplified exposure to major tech stocks but carrying significant decay and volatility risks. Investment opportunity exists for aggressive traders betting on sustained tech sector strength, while the primary risk is rapid capital erosion during market downturns or flat periods, as evidenced by recent performance gaps versus the underlying index.